DOCSLIB.ORG

Proceedings - Small Animals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proceedings - Small Animals 30thAnnual Scientific Meeting Online Proceedings - Small Animals 8-10 July 2021 MEDTRONIC ANIMAL HEALTH VersaOne™ SurgiSleeve™ access platform wound protector DST Series™ GIA™ single use reloadable staplers Elevision™ HD 1 Complete suture range System Capnostream™ 35 portable respiratory monitor Valleylab™ LS10 energy platform Nellcor™ Portable SpO₂ Valleylab™ WarmTouch™ WT 6000 Patient Monitoring FT10 energy platform warming unit System © 2021 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. ™* Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Photo credit: iStock. 21-weu-ecvs-digital-advert-5399963 medtronic.com/covidien/uk Surgery careers within IVC Evidensia Referrals IVC Evidensia Referrals is a network of veterinary clinics and hospitals offering a range of referral services to first opinion vets. “At IVC Evidensia we understand just how important and central surgery is to delivering the highest quality patient care in our multidisciplinary sites.” - AMANDA BOAG, GROUP REFERRALS DIRECTOR - IVC EVIDENSIA OUR MISSION Working with our colleagues in general practice, staff throughout the IVC Evidensia referral network deliver exceptional veterinary care to thousands of patients and their owners every year. Investing in individuals, teams and facilities is at the heart of what we do to facilitate seamless referrals across Europe. OUR REFERRAL HOSPITALS Typically run by Specialists or Advanced Veterinary Practitioners, our vast and extensive network of referral hospitals, centres and service providers cover the UK, the Nordics and mainland Europe. WHAT’S IN IT FOR YOU? As part of a young, dynamic network that is still growing, there are many opportunities for specialists that work within the network. We welcome discussions with individuals on how we can assist with achieving personal and career, aspirations and motivations. With a referrals network of over 170 referral centres, hospitals, out- of-hours clinics and sites offering referral services,, we are continually seeking to grow our teams and their expertise by offering: • continuous professional development (CPD) • career progression • evidence-based veterinary medicine • work-life balance “We support our Europe wide surgery teams with state-of-the-art WE’RE HIRING! facilities and instrumentation along with excellent peer networking, We are constantly searching for the best we are dedicated to clinical excellence and are committed to build veterinary surgeons from Europe and more residency programmes – come join us and be part of a very around the world. exciting future.” Open applications are always welcome - PROF JOHN WILLIAMS DIPECVS, NATIONAL SURGICAL LEAD - VETS NOW so please email our dedicated referral WHAT TRAINING SUPPORT IS AVAILABLE? recruitment consultant Rebecca Coleman We have an array of training and support options available which can be to explore your options in joining used as part of a tailored plan for individuals’ dependent on their current Europe’s leading veterinary care provider specifics and what their next planned career move entails. - [email protected]. Ranging from structured one-off courses, training programmes, internships, residencies, financial and mentoring support, we have a wide range of options available and continue to add to these. WHEREVER YOU ARE IN YOUR CAREER, WE HAVE OPPORTUNITIES FOR YOU For more information about IVC Evidensia Referrals, please visit our website: https://www.ivcevidensia.com/referral-guide And for careers opportunities with us, please visit: https://www.ivcevidensia.co.uk/referral-careers Meeting The Rising Demand For Orthopaedic Surgery Following a pandemic pet boom and over 3.2m households adopting pets in the UK alone, the subsequent demand for Orthopaedic surgery is anticipated to increase 8.4% annually. If you are looking to develop partnerships which can meet this demand, deliver quantifiable value to your clinical service, whilst adopting products and technologies which provide you with the ultimate piece of mind, our extensive portfolio of over 3,000 specialist Orthopaedic products could be the solution. Over 19,000 Vi products are being implanted each year Regulated to ISO9001 quality standards in over 65 countries worldwide With a reported revision rate of 0.1%, validation and From our work with Practices to date, a typical 15% product efficacy are achieved through clinical outcomes, cost saving can be achieved, developing leaner Practices rivalling any fracture repair system and all without any impact on the patient outcome A true partnership approach. Our team of fully With over 1,400 different plate and screw profiles, we qualified nurses with over90 years in-Practice deliver a comprehensive & dynamic portfolio experience, deliver a seamless identification and order processing experience @VeterinaryInstrumentation W: www.vetinst.com @Veterinary Instrumentation, a Covetrus Company Veterinary Instrumentation, Distington House, 26 Atlas Way, Sheffield, S4 7QQ The ECVS thanks all sponsors supporting the ECVS online Annual Scientific Meeting 2021 Contents Thursday 08 July, 2021 Resident Forum Orthopaedic Biomechanical Comparison of Locking and Non-locking Constructs in a Feline Ilial Fracture Model – an ex vivo Cadaveric Study Paulick PL1, Knell KSC*1, Smolders SLA1, Pozzi PA*1, Ferguson FSJ2, Schmierer SPA*1 Long-term clinical outcome and osteoarthritis score for 54 dogs affected by osteochondritis dissecans of the humeral head treated with arthroscopic debridement or not: a retrospective multi-center study. Job C1, Caron A*2, Cachon T*3, Carozzo C*3, Viguier E*3, Deprey J3, Brincin M2, Guillemot A2, Maitre P*1, Bureau S*1 Micro-computed tomographic (Micro-CT) assessment of different contrast preparations for canine cadaveric microangiographic assessment of the hindlimbs Inness PRP, Hall E, Johnson KA* Comparison of canine femoral torsion measurements using the axial and biplanar methods on 3-dimensional volumetric reconstructions of computed tomography images Serck B1, Karlin M*2, Kowaleski M*2 Effect of working length and plate-bone distance on 2.0mm locking construct stiffness in a diaphyseal fracture gap model Evans A1, Glyde M*1, Hosgood G*1, Day R2 Effect of Osteotomy and Plate Orientation on Rock-Back Following Tibial Plateau Leveling Osteotomy Using a Tibial Gap Model Bula E, Abdullatif M, Chung WC, Mukherjee R, Dejardin LM* CT evaluation of completeness of arthroscopic subtotal coronoidectomy for treatment of canine medial coronoid disease Renner C, Medl N* Modified Fulkerson Procedure (MFP): A potential new osteotomy technique to treat concurrent cranial cruciate ligament disease and medial patella luxation in dogs. Fontalba Navas JL1, Marcellin-Little DJ*2, Senis E3, Artiles A4, Calvo I*1 Mechanical contribution of the fibula to torsional stiffness and strength of the canine crus. Picavet PP, Balligand M* Comparative kinematic evaluation of TPLO and TPLO combined with extra-articular stabilization: a biomechanical study Husi B, Park BH, Lampart M, Pozzi A* Resident Forum Soft Tissue Comparison of conventional ligatures and a vessel sealing device during open ovariohysterectomy in rabbits Dumartinet C, Bernardé A*, Bernard F* Effect of patient positioning on retrieval of cystoliths by percutaneous cystolithotomy in dogs. Knight R, Owen L* Histologically tumour-free margins following planned marginal excision of soft-tissue sarcomas and mast cell tumours with intent for radiotherapy Haine DLH, Pittaway R, Berlato D, Demetriou J* Comparison of a single-access glove port with a SILS™ port in a surgical simulator model using MISTELS Strohmeier U1, Dupré G*2, Bockstahler B1, Tichy A3, Liehmann L*1 Comparison of outcome between dogs with gastric dilatation volvulus syndrome surgically treated immediately after a brief resuscitation or after a prolonged fluid resuscitation. Lhuillery E1, Libermann S1, Velay L1, Le Boedec K2, Gautherot A1, Bonneau L1, Etchepareborde S*1 Long-term outcome of surgical treatment of perineal hernia in 36 cats (2013-2019) Hubers MWL, Vink JWG, Van Klaveren NJ*, Sjollema BE Comparison of median sternotomy closure-related complication rates using wire and suture in dogs: a multicentric retrospective study Pilot MA1, Lutchman A2, Hennet J3, Anderson D*3, Robinson W*4, Horton H4, Rossanese M5, Chrysopoulos A6, Demetriou J*6, De la Puerta B*7, Mullins R*8, Kirby B9, Brissot H*9, Jeffery N*10, Chanoit G*1 Intraoral approach for zygomatic sialoadenectomy in dogs: an ex-vivo study Viitanen J1, De Rooster H*1, Kitshoff AM*2, Boaz A3, Devriendt N*1 Outcome for septic peritonitis in cats treated surgically in the United Kingdom Anderson T1, Beever L*2, Moores A*3, Llanos C4, Coppola M5, Bowlt-Blacklock K*6, Hall J*7, Barnes D*1 Long-term outcomes following cholecystectomy in cats Simpson MS, Neville-Towle JNT*, Rossanese MR Friday 09 July, 2021 Current strategies for: Current strategies for dealing with critical bone defects / non-union Marshall WG* Dealing with cartilage defects Böttcher P* Shearing injuries and open fractures Kulendra ER* ECVS + VSSO Sentinel lymph node mapping in the clinical staging of oncological patients: indications, techniques and results Brissot HN* Conservative approach of the management of soft tissue sarcomas - guidelines and controversies Buracco P* Canine Apocrine Gland Anal Sac Adenocarcinoma: A Clinical Staged Approach for Optimizing Treatment Options and Prognosis Liptak JM* Prosthetic Reconstruction
Load more

Recommended publications
  • Outcome and Clinical, Pathological, and Immunohistochemical Factors
    Small Animals Outcome and clinical, pathological, and immunohistochemical factors associated with prognosis for dogs with early-stage anal sac adenocarcinoma treated with surgery alone: 34 cases (2002–2013) Katherine A. Skorupski DVM OBJECTIVE To determine survival time and metastatic rate for dogs with early-stage Christina N. Alarcón DVM anal sac adenocarcinoma (ASACA) treated with surgery alone and assess Louis-Philippe de Lorimier DVM whether specific clinical, pathological, or immunohistochemical factors Elise E. B. LaDouceur DVM were predictive of outcome for those dogs. Carlos O. Rodriguez DVM, PhD DESIGN Retrospective case series. Robert B. Rebhun DVM, PhD From the Departments of Veterinary Surgical and ANIMALS Radiological Sciences (Skorupski, Rodriguez, Rebhun) 34 dogs with early-stage, nonmetastatic ASACA that were treated with and Veterinary Pathology, Microbiology, and Immunol- surgery only. ogy (Alarcón, LaDouceur), School of Veterinary Medi- cine, University of California-Davis, Davis, CA 95616; PROCEDURES and the Centre Vétérinaire Rive-Sud, 7415 Taschereau Medical record databases of 2 referral hospitals were searched to identify Blvd, Brossard, QC J4Y 1A2, Canada (de Lorimier). Dr. Alarcón’s present address is Biomedical Sciences dogs examined between 2002 and 2013 that had a diagnosis of nonmeta- Program, University of California-San Diego, La Jolla, static ASACA that was < 3.2 cm at its largest diameter. Only dogs that CA 92093. Dr. LaDouceur’s present address is Joint received surgical treatment alone were included in the study. For each dog, Pathology Center, 606 Stephen Sitter Ave, Silver information extracted from the medical record included signalment, clini- Spring, MD 20910. Dr. Rodriguez’s present address is Vista Veterinary Specialists, 7425 Greenhaven Dr, Sac- cal and diagnostic test findings, tumor characteristics, and outcome.
    [Show full text]
  • Canine Anal Sac Adenocarcinomas: Clinical Presentation and Response to Therapy
    J Vet Intern Med 2002;16:100–104 Canine Anal Sac Adenocarcinomas: Clinical Presentation and Response to Therapy Peter F. Bennett, Denis B. DeNicola, Patty Bonney, Nita W. Glickman, and Deborah W. Knapp A retrospective study of 43 dogs with anal sac adenocarcinoma (ASAC) was performed to characterize the clinical presentation and response to treatment. Clinical signs at presentation varied considerably, with signs related either to sublumbar nodal metastasis (tenesmus or constipation) or hypercalcemia (polyuria-polydipsia and anorexia) being the most frequent findings. At the time of presentation, 23 (53%) dogs had hypercalcemia and 34 (79%) had metastases, with the regional lymph nodes (31 dogs, 72%) being the most common site of metastasis. A variety of chemotherapeutic agents were administered, with partial remission (PR) recorded in 4 of 13 (31%) dogs treated with cisplatin and in 1 of 3 (33%) dogs treated with carboplatin. The median survival for all dogs was 6 months (range, 2 days–41 months). There was no statistical association between the presence of hypercalcemia and survival, although the power of the study to detect an increase in survival of 3 months was low (.33). We conclude that platinum chemo- therapy has antitumor activity in canine apocrine gland carcinoma and that further study of these agents is warranted. Key words: Anal tumors; Chemotherapy; Dog; Surgery. nal sac disease in the dog is common and affects ap- Clinical signs of ASAC are varied, and signs relate to A proximately 12% of the canine population.1 The ma- the size of the tumor at presentation and whether hyper- jority of anal sac disease consists of impactions and infec- calcemia is present.
    [Show full text]
  • ANAL SAC ADENOCARCINOMA Suzanne Rau, DVM, DACVIM (Oncology)
    VOLUME 8 ISSUE 1 • 2019 WINTER EDITION ANAL SAC ADENOCARCINOMA Suzanne Rau, DVM, DACVIM (Oncology) Apocrine gland anal sac adenocarcinomas direct extension of tumor from the (AGASACA) comprise about 17% sublumbar lymph nodes to the lumbar percent of perianal malignancies, vertebrae can occur. and 2% of all skin and subcutaneous tumors. The average age at diagnosis TREATMENT is nine to eleven years. Treatment for this disease involves both local control of the primary mass itself, DIAGNOSIS AND STAGING as well as controlling tumor metastasis. Some dogs with AGASACA present with signs related to the mass itself, SURGERY such as a swelling in the perianal region, Surgery to remove the primary mass a mass palpated on routine rectal in the anal region and/or removal of exam, scooting, or straining to defecate. enlarged sublumbar lymph nodes Other dogs may present for signs within the abdomen is often the first step. indirectly related to the mass if the Ideally these tumors should be removed tumor is causing hypercalcemia, with wide margins, however, given Dr. Suzanne Rau which is reported to occur in about their close proximity to the rectum and 25% of dogs with AGASACA. These important neurovascular structures, hypercalcemic dogs may be polyuric resection is often marginal. and polydypsic. aortic bifurcation. However, they are Risk of incontinence is low and typically usually well encapsulated and can be The reported rate of metastasis at the transient with unilateral anal sacculectomy, successfully removed without major time of diagnosis ranges from 50-80%. and only slightly increased for bilateral complications. Therefore, prior to surgery and other anal sacculectomy; bilateral anal sac therapies, staging with three view chest tumors have been reported in RADIATION THERAPY x-rays and an abdominal ultrasound approximately 10% of cases.
    [Show full text]
  • Malignant Perineal Tumors in Dogs: the Contribution of Computed Tomography for Staging and Surgical Planning1 Carla A.B
    Pesq. Vet. Bras. 38(12):2241-2245, dezembro 2018 DOI: 10.1590/1678-5150-PVB-5822 Original Article Pequenos Animais/Small Animals Diseases ISSN 0100-736X (Print) ISSN 1678-5150 (Online) PVB-5822 SA Malignant perineal tumors in dogs: the contribution of computed tomography for staging and surgical planning1 Carla A.B. Lorigados2*, Ana Carolina C.B. Fonseca Pinto3, Julia Maria Matera3, and Diego F.A. Modena3 ABSTRACT.- Lorigados C.A.B, Fonseca Pinto A.C.C.B., Matera J.M. & Modena D.F.A. 2018. Malignant perineal tumors in dogs: the contribution of computed tomography for staging and surgical planning. Pesquisa Veterinária Brasileira 38(12):2241-2245. SPDepartamento 05508-270, deBrazil. Cirurgia, E-mail: Faculdade de Medicina Veterinária e Zootecnia, Universidade de São Paulo, Avenida Prof. Dr. Orlando Marques de Paiva 87, Cidade Universitária, São Paulo, [email protected] The contribution of computed tomography for staging and surgical planning of malignant perineal tumors in dogs is discussed. Five dogs diagnosed with malignant perineal neoplasms underwent to computed tomography (CT) examination. The CT image enabled investigation of cleavage planes between neoplastic lesions and adjacent structures such as the rectum, anus, vagina, urethra and perineal muscles. Accurate assessment regional lymph nodes and adjacent bone structures was also possible. All tumors evaluated in this region presented heterogeneous appearance in pre and postcontrast CT images, but only the anal sac adenocarcinomas presented lymphadenopathy. Computed tomography proved to be a valuable tool for tumor staging and determination of lesion extension and invasion of adjacent tissues, providing significant contributions to clinical and surgical therapeutic planning.
    [Show full text]
  • Anal Sac (Apocrine Gland) Adenocarcinoma Handout
    Anal sac (apocrine gland) adenocarcinoma Anal sac adenocarcinoma is a malignant tumour that occurs within the anal sacs, located beneath the skin on either side of the anus. These tumours arise from sweat glands within the lining of the sacs. These glands normally secrete a foul smelling liquid that coats the faeces or stool, similar to the scent glands found in skunks. Tumours of the anal sac are almost always malignant and tend to affect dogs over 8 years of age. As with most tumours in animals (and people) we do not know what causes them to occur. Clinical signs The most common presenting complaints include local irritation, bleeding, straining to defecate, scooting and licking of the anus. Often the tumour cannot be seen but occasionally there will be a visible mass or swelling around the rectum. In some patients enlarged internal lymph nodes can cause changes in stools (i.e. flat and ribbon-like) or straining to defecate. Approximately 25% of anal gland tumours can produce a hormone that results in increased blood calcium levels (hypercalcaemia). This can lead to increased water consumption, increased urination, weight loss, weakness or vomiting. Some anal gland tumours are discovered as incidental findings during routine examination. Diagnosis and staging To diagnose an anal sac tumour a fine needle aspirate or biopsy is performed. Once a diagnosis has been made further tests (staging) are recommended to screen for cancer spread to internal organs (these are called metastases). Anal sac adenocarcinomas can metastasise early and have often already spread to the abdominal lymph nodes before the diagnosis has been made.
    [Show full text]
  • Canine Apocrine Gland Anal Sac Adenocarcinoma (AGASACA)
    MEDICAL ONCOLOGY Canine Apocrine Gland Anal Sac Adenocarcinoma (AGASACA) WHAT IS AN ANAL GLAND TUMOR? Apocrine gland anal sac adenocarcinomas (AGASACA) are malignant tumors of the anal glands. These are paired glands located on either side of the rectal opening. Anal glands are sweat glands that contain a brown, malodorous liquid that is eliminated upon defecation. AGASACAs are locally invasive tumors with a high rate of metastasis to regional lymph nodes (including sublumbar and medial iliac lymph nodes inside the abdomen and inguinal nodes located in the groin). Tumors can also spread to distant sites including the liver, spleen, and lungs. Metastasis is possible even in cases where the primary tumor is only a few millimeters in size. Tumor cells sometimes secrete a hormone that causes blood levels of calcium to rise above normal. Dogs affected with high blood calcium levels show increased thirst, urination, lethargy, and in some cases this can lead to severe heart and kidney damage. Spaniels are affected more frequently than other breeds. Typically, only one gland is affected, however disease can occur in both glands either simultaneously or several years apart. WHAT ARE THE CLINICAL SIGNS? Clinical signs include “scooting,” licking/chewing the affected area, straining to defecate and/or urinate, constipation, bloody stool, vomiting, decreased appetite, lethargy (weakness/tiredness), increased thirst or urination, or an external swelling in the rectal region. The mass may be found incidentally on routine physical examination or by a groomer attempting to empty a pet’s anal glands. WHAT DIAGNOSTICS ARE PERFORMED? If an anal gland mass is noted on examination, a fine needle aspirate is recommended.
    [Show full text]
  • Evaluation of Expression and Function of VEGFR-2, PDGFR-Α, PDGFR-Β
    Evaluation of Expression and Function of VEGFR2, PDGFRα, PDGFRβ, KIT, and RET in Canine Apocrine Gland of the Anal Sac Adenocarcinoma and Thyroid Carcinoma Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Bridget Karen Urie, BS, MA, DVM Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2012 Thesis Committee: Cheryl A. London, DVM, PhD, DACVIM, Co-Advisor William C. Kisseberth, DVM, PhD, DACVIM, Co-Advisor Ducan S. Russell, BMVS [Hons], DACVP Copyrighted by Bridget Karen Urie 2012 Abstract Biological responses to toceranib phosphate have been reported in both canine apocrine gland anal sac adenocarcinomas (AGASACA) and thyroid carcinomas (TC). However, little is known about the molecular biology of either of these tumor types and the mechanism of the biological activity of toceranib. In the present study, we investigated the presence and expression of known targets of toceranib and interrogated AGASACA and TC samples for the expression of VEGFR2, PDGFR, KIT and RET at both the message and protein level to begin to dissect the molecular basis for this observed activity. Samples from 24 primary AGASACA, 11 with paired metastatic lymph nodes, and 15 TC were evaluated using reverse-transcriptase polymerase chain reaction for detection of mRNA, phosphoprotein arrays to screen for evidence of protein phosphorylation, and tissue microarrays for immunohistochemical evaluation of protein expression. Messenger RNA from VEGFR2, PDGFR, KIT and RET was detected in all AGASACA samples. Messenger RNA for VEGFR2, PDGFR, and Kit was detected in all TC samples, while mRNA for Ret was amplified in 10/15 TC samples.
    [Show full text]
  • Clinical Consults What’S Your Diagnosis?
    Volume 11 | Issue 10 | December 2019 Clinical Consults What’s Your Diagnosis? PATIENT HISTORY RECTAL EXAMINATION— SIGNALMENT: “Chelsea” is a 7.5-year-old female spayed Labradoodle. Weight Important In Every Sick and Well Patient! 70 lb/34 kg. PERTINENT PAST HISTORY: “Chelsea” has been a very healthy dog. She has experienced historical intermittent urinary Donna J. Spector , DVM, DACVIM, Internal Medicine tract infections (UTIs) but no other major systemic issues. She eats dry adult commercial dog food. She is current on recommended vaccinations and takes monthly preventatives as recommended by TABLE 1. her primary care veterinarian. “CHELSEA’S” BLOODWORK CURRENT HISTORY: “Chelsea” had recently Calcium (ref. range 8.4-11.8 mg/dL) 18.9 mg/dL begun experiencing an increase of urination Phosphorus (ref. range 2.5-6.1 mg/dL) 2.9 mg/dL and urinary accidents in the house. The owner initially did not describe an BUN (ref. range 9-31 mg/dL) 42 mg/dL accompanying increase of water drinking. (ref. range 0.5-1.5 mg/dL) 1.6 mg/dL The owner brought in a free-catch urine Creatinine sample for analysis which revealed pyuria ALKP (ref. range 5-160 U/L) 177 U/L (20-30 WBC/hpf) and rare bacteria. “Chelsea” was prescribed amoxicillin 500 mg USG 1.012 PO BID for 7 days to treat a presumptive UTI. The owner reported the amoxicillin helped Chelsea” was diagnosed with severe hypercalcemia and mild renal failure likely secondary to the with the clinical signs for a short period but severe hypercalcemia. An Internal Medicine consultation was recommended ASAP.
    [Show full text]
  • Volume 7, Issue 3 V4.Indd
    VETcpd - Oncology Peer Reviewed Canine anal sac adenocarcinoma – a review Anal sac adenocarcinoma is the most common malignant neoplasm arising from canine anal sacs. Metastasis, particularly to the local lymph nodes, is a relatively frequent feature of the disease and paraneoplastic hypercalcaemia can result. Thorough staging is therefore indicated once a diagnosis of anal sac adenocarcinoma has been made. Surgical excision of the affected anal sac is the treatment of choice for the primary tumour and concurrent lymphadenectomy Julia Riggs is advocated where regional nodal metastasis has occurred. Chemotherapy and MA VetMB AFHEA DipECVS MRCVS radiotherapy may also be used alongside or instead of surgery to help manage EBVS European Specialist in the disease. Unfortunately, the majority of dogs with a diagnosis of anal sac Small Animal Surgery adenocarcinoma will develop progressive disease in spite of treatment and therefore RCVS Specialist in repeat staging is usually recommended. Small Animal Surgery By incorporating evidence from the recent veterinary literature, this article will review Having completed a surgical residency at the diagnostic and therapeutic options for canine anal sac adenocarcinoma and the University of Cambridge and passed outline the prognosis for dogs affected by this disease. the certifying examinations, Julia became Key words: Anal sac, anal sac adenocarcinoma, apocrine gland a European Specialist in Small Animal adenocarcinoma, anal sacculectomy Surgery in 2018. She subsequently spent two years working as a Soft Tissue Surgeon in a private referral practice Introduction before returning to work in the Soft Anal sac adenocarcinoma is a highly Barnes and Demetriou 2017; Skorupski Tissue Surgery team at the University of malignant neoplasm arising from the et al.
    [Show full text]
  • Anal Sac Adenocarcinoma; Not Always a Pain in the Rear
    October 2012, Issue 48 Hope you have a safe & In This Issue Happy Halloween AMVS Event Updates Upcoming Events! Anal Sac Adenocarcinoma; Not Always a Pain in the Rear In addition to our regular ER hours, From AMVS provides Aspen Meadow emergency and Veterinary Specialists critical care services to your patients AMVS Event Updates! Fridays, all day CALL AECC & AMVS's CE on October 25th had a great turn out, 303-678-8844 We hope that those of you that attended had a great time and learned a lot about how to treat common toxicity poisoning and look forward to seeing you all at our CE's in the winter. Upcoming Events! AMVS will be taking family and pet holiday portraits with Santa, at our facility in Longmont, CO so keep your AMVS is: eyes open for more PACE certified, information to be announced... LEED certified, and You can also find information a zero-waste about our upcoming events by checking out our facebook page. facility. Simply click on the link below. Anal Sac Adenocarcinoma; Not Always a Pain in the Rear By: Jim Perry, DVM, PhD, DACVIM Oncologist; Orthopedic Surgical Resident Practice Points: 1. Anal sac adenocarcinoma is a top differential in any Archives of our past animal presenting with hypercalcemia newsletters containing timely 2. Metastasis is present at the time of diagnosis in greater and useful medical than 50% of animals with anal sac adenocarcinoma; information are on staging should included blood work, UA, thoracic our website. radiographs and abdominal ultrasound. 3. Surgery is the mainstay of treatment even when metastatic disease is evident within the local lymph nodes.
    [Show full text]
  • Anal Sac Adenocarcinoma; a Hidden Cancer
    Research & Development Anal Sac Adenocarcinoma; A Hidden Cancer Tumours of the perianal region occur frequently in dogs Metastatic Disease (Bennett et al. 2002), with benign adenomas comprising 58- In many cases, the primary lesion may be asymptomatic and 96% of tumours at this site (Turek & Withrow 2013). In some the dog presents with signs consistent with metastasis to the cases these may transform to become malignant perianal regional lymph nodes (medial iliac, sacral, hypogastric, pelvic adenocarcinomas, and these need to be distinguished from etc.) (Williams et al. 2003; Polton & Brearley 2007; Wouda adenocarcinomas which derive from the apocrine secretory et al. 2013). Metastatic disease in this region can present epithelium within the wall of the anal sacs (Polton & Brearley as difficulty passing faeces, straining to defecate, abnormal 2007). Neoplasia of the squamous epithelial lining of the posturing or altered faecal shape. Although less common, anal sac is uncommon (Polton et al. 2006; Mellett et al. 2014). metastasis to bone can be seen. A single case report of a Anal gland/sac adenocarcinomas (ASA) represent 2% of all young dog presenting with progressive hind limb ataxia and skin and subcutaneous tumours in dogs, and around 17% paresis, worsening to paralysis over a short period of time, was of all perianal malignancies (Bennett et al. 2002; Turek attributed to an anal sac adenocarcinoma with metastatic & Withrow 2013; Potanas et al. 2015). They are clinically spread to the vertebrae and subsequent pathological important because of their high metastatic potential and fractures (Bray 2011). association with paraneoplastic hypercalcaemia; this review will therefore focus on this tumour type (Polton et al.
    [Show full text]
  • Care Beyond a Cure: Extraordinary Advances in Cancer Care 2014
    COMPASSIONATE CANCER CARE Care Beyond a Cure: Extraordinary Advances in Cancer Care 2014 Gregory K. Ogilvie, DVM, Diplomate ACVIM (Specialties of Internal Medicine, Oncology), Diplomate ECVIM-CA (Oncology) Director, CVS Angel Care Cancer Center President, Special Care Foundation for Companion Animals Professor, Division Director, University of California San Diego Veterinary Oncology 2310 Faraday Ave Carlsbad, CA, USA http://www.CVSAngelCare.com http://SpecialCareFoundation.org http://radonc.ucsd.edu/fands/faculty.asp COMPASSIONATE CANCER CARE Dr. Ogilvie is director of the Angel Care Cancer Center at California Veterinary Specialists as well as Professor and Division Director of Veterinary Oncology, Department of Radiation Medicine and Applied Sciences, University of California-San Diego, Moores Cancer Center. Prior to his move to Southern California, Greg was a full tenured professor, internist, and head of medical oncology and director of the Medical Oncology Research Laboratory, Animal Cancer Center at Colorado State University from 1987 until 2003. During this 16 year period at CSU, Greg also spent one year on sabbatical teaching and developing new, innovative cancer therapies at the medical school and the Laboratoire Nutrition, Croisance et Cancer at the Université François Rabelais in Tours France. Dr. Ogilvie received his DVM from Colorado State University and was in private practice in Connecticut before completing a residency at Tufts University/Angell Memorial Animal Hospital. From there he joined the faculty as a professor at the University of Illinois before moving on to his professorship in Colorado. Dr. Ogilvie is board certified in both the specialties of both internal medicine and oncology by the American College of Veterinary Internal Medicine and in oncology and is a Diplomate of the European College of Veterinary Internal Medicine-Companion Animals, Specialty of Oncology.
    [Show full text]